Expression and regulation of the evi-1 gene in the human factor-dependent leukemia cell line, UCSD/AML1.

Abstract:

:The human factor-dependent leukemia cell line UCSD/AML1 contains the t(3;3) (q21;q26) characteristic of the syndrome of acute leukemia with high platelets. The human homologue of the murine leukemia oncogene evi-1 was recently localized to chromosome 3q24-3q28 and transcription of evi-1 is a frequent event in mouse-retrovirus-induced leukemias (17). To determine whether translocations near human 3q24 might induce similar genetic changes, we examined and compared evi-1 and c-myc expression and regulation in UCSD/AML1 cells. Steady-state evi-1 transcripts were detected in UCSD/AML1 and murine leukemia M1 cells, but were not present in HL60 or Namalwa human leukemia cells. Transcription assays showed the evi-1 gene was actively transcribed in UCSD/AML1, but not HL60 nuclei. Evi-1 transcript sizes and half-life were similar in UCSD/AML1 and human HEC-1B carcinoma cells which express evi-1 transcripts, but do not have abnormalities involving chromosome 3. An alternative splice site detected by polymerase chain reaction was present in transcripts from both cell lines. Regulation of evi-1 RNA in UCSD/AML1 cells was similar to that of actin transcripts in response to cycloheximide or phorbol-ester-induced macrophage differentiation. After withdrawal of granulocyte/macrophage colony-stimulating factor (GM-CSF), evi-1, actin, and histone H3 transcripts declined in concert with exit from the cell cycle. Minor differences in rates of recovery were noted for these three genes after GM-CSF restimulation. In contrast, c-myc was expressed at high levels in UCSD/AML1 cells and showed evidence for specific regulation in response to cycloheximide, phorbol ester, and GM-CSF withdrawal and restimulation. These studies suggest the 3q translocation in UCSD/AML1 cells is associated with evi-1 transcription and expression of a potential transforming gene. In contrast to c-myc, evi-1 expression is minimally altered by biologically active chemicals or growth factor stimulation.

journal_name

Leukemia

journal_title

Leukemia

authors

Oval J,Smedsrud M,Taetle R

subject

Has Abstract

pub_date

1992-05-01 00:00:00

pages

446-51

issue

5

eissn

0887-6924

issn

1476-5551

journal_volume

6

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract::We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403667

    authors: Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期:2005-04-01 00:00:00

  • Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

    abstract::Galectins constitute a family of lectins that specifically exhibit the affinity for beta-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate recognition domains and has recently been shown to have an anti-proliferative effect on cancer cells. We invest...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.25

    authors: Kobayashi T,Kuroda J,Ashihara E,Oomizu S,Terui Y,Taniyama A,Adachi S,Takagi T,Yamamoto M,Sasaki N,Horiike S,Hatake K,Yamauchi A,Hirashima M,Taniwaki M

    更新日期:2010-04-01 00:00:00

  • Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

    abstract::Promising new drugs are being evaluated for treatment of multiple myeloma (MM), but their impact should be measured against the expected outcome in patients failing current therapies. However, the natural history of relapsed disease in the current era remains unclear. We studied 286 patients with relapsed MM, who were...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2011.196

    authors: Kumar SK,Lee JH,Lahuerta JJ,Morgan G,Richardson PG,Crowley J,Haessler J,Feather J,Hoering A,Moreau P,LeLeu X,Hulin C,Klein SK,Sonneveld P,Siegel D,Bladé J,Goldschmidt H,Jagannath S,Miguel JS,Orlowski R,Palumbo A,

    更新日期:2012-01-01 00:00:00

  • Detection of residual proliferating leukemic cells by fluorescence in situ hybridization in CML patients in complete remission after interferon treatment.

    abstract::Interferon-alpha produces a complete hematologic and cytogenetic remission in approximately 20% of patients with chronic myelogenous leukemia (CML). In this study, we applied fluorescent in situ hybridization (FISH) methodology to examine the possibility that a low level of proliferating Philadelphia-chromosome-positi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Zhao L,Kantarjian HM,Van Oort J,Cork A,Trujillo JM,Liang JC

    更新日期:1993-02-01 00:00:00

  • Correction: Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients.

    abstract::Following the publication of this article, the authors noted that Patrick M. Vanderboom was inadvertently omitted from the author list. The correct author list is as follows: Sanjay Kumar, David Murray, Surendra Dasari, Paolo Milani, David Barnidge, Benjamin Madden, Patrick M. Vanderboom, Taxiarchis Kourelis, Bonnie A...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-019-0405-0

    authors: Kumar S,Murray D,Dasari S,Milani P,Barnidge D,Madden B,Kourelis T,Arendt B,Merlini G,Ramirez-Alvarado M,Dispenzieri A

    更新日期:2019-04-01 00:00:00

  • Molecular remission as a therapeutic objective in acute promyelocytic leukemia.

    abstract::Acute promyelocytic leukemia (APL) is a subtype of acute leukemia characterized by a unique t(15;17) translocation generating the PML/RARA fusion gene and hybrid oncoprotein. Besides its critical role in leukemogenesis, this genetic aberration serves as a disease-specific biomarker for rapid diagnosis and monitoring o...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-018-0219-5

    authors: Cicconi L,Fenaux P,Kantarjian H,Tallman M,Sanz MA,Lo-Coco F

    更新日期:2018-08-01 00:00:00

  • Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers.

    abstract::Sequential analysis of chimerism after allogeneic blood stem cell transplantation (BSCT) has been shown to be predictive for graft failure and relapse. We have explored the impact of a novel approach for the quantitative determination of chimerism using a commercial PCR assay with multiplex amplification of nine STR-l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401953

    authors: Thiede C,Bornhäuser M,Oelschlägel U,Brendel C,Leo R,Daxberger H,Mohr B,Florek M,Kroschinsky F,Geissler G,Naumann R,Ritter M,Prange-Krex G,Lion T,Neubauer A,Ehninger G

    更新日期:2001-02-01 00:00:00

  • Characterization of acute lymphoblastic leukemia of childhood by immunoglobulin and T-cell receptor gene patterns.

    abstract::Molecular biological studies of immunoglobulin (Ig) and T-cell antigen receptor (TCR) genes provide novel approaches to the identification and characterization of the acute lymphoblastic leukemias (ALL). Such studies greatly enhance our understanding of both the cells of origin in these diseases and the order of assem...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Felix CA,Poplack DG

    更新日期:1991-12-01 00:00:00

  • Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-020-0782-4

    authors: Weisberg E,Meng C,Case A,Sattler M,Tiv HL,Gokhale PC,Buhrlage S,Wang J,Gray N,Stone R,Liu S,Bhagwat SV,Tiu RV,Adamia S,Griffin JD

    更新日期:2020-09-01 00:00:00

  • Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies.

    abstract::The nuclear export receptor, Exportin 1 (XPO1), mediates transport of growth-regulatory proteins, including tumor suppressors, and is overactive in many cancers, including chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and aggressive lymphomas. Oral selective inhibitor of nuclear export (SINE) compou...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.136

    authors: Hing ZA,Fung HY,Ranganathan P,Mitchell S,El-Gamal D,Woyach JA,Williams K,Goettl VM,Smith J,Yu X,Meng X,Sun Q,Cagatay T,Lehman AM,Lucas DM,Baloglu E,Shacham S,Kauffman MG,Byrd JC,Chook YM,Garzon R,Lapalombella R

    更新日期:2016-12-01 00:00:00

  • All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase.

    abstract::Since in vitro observations indicated that all-trans retinoic acid (ATRA), especially in combination with IFNalpha, can exert significant suppressive effects on Ph+ cells, we investigated the effects and the pharmacokinetic profile of ATRA in a selected cohort of patients with Ph+ chronic myeloid leukemia (CML) in chr...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2400988

    authors: Russo D,Regazzi M,Sacchi S,Visani G,Lazzarino M,Avvisati G,Pelicci PG,Dastoli G,Grandi C,Iacona I,Candoni A,Grattoni R,Galieni P,Rupoli S,Liberati AM,Maiolo AT

    更新日期:1998-04-01 00:00:00

  • Rearranged T-cell receptor beta genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia.

    abstract::Current MRD studies in T-cell acute lymphoblastic leukemia (T-ALL) mainly use T-cell receptor gamma, delta and SIL-TAL1 gene rearrangements as MRD-PCR targets. However, low frequency or limited diversity of these markers restricts the number of evaluable patients, particularly because two markers are recommended for M...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403263

    authors: Brüggemann M,van der Velden VH,Raff T,Droese J,Ritgen M,Pott C,Wijkhuijs AJ,Gökbuget N,Hoelzer D,van Wering ER,van Dongen JJ,Kneba M

    更新日期:2004-04-01 00:00:00

  • Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936.

    abstract::Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in mature T-cell neoplasms. However, lack of standardized primers and PCR protocols has hampered comparability of data in previous clonality studies. To obtain referenc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404481

    authors: Brüggemann M,White H,Gaulard P,Garcia-Sanz R,Gameiro P,Oeschger S,Jasani B,Ott M,Delsol G,Orfao A,Tiemann M,Herbst H,Langerak AW,Spaargaren M,Moreau E,Groenen PJ,Sambade C,Foroni L,Carter GI,Hummel M,Bastard C,D

    更新日期:2007-02-01 00:00:00

  • SIV/HIV-1 chimeric viruses having HIV-1 env gene: a new animal model and a candidate for attenuated live vaccine.

    abstract::In order to generate an HIV-1, which is infectious to and induces AIDS-like disease in monkeys, an SIVmac/HIV-1 chimeric virus, designated NM-3rN, which was replication-competent in monkeys, was constructed by recombination between HIV-1 and SIV mac genomes. The NM-3rN enabled to evaluate the efficacy of HIV-1 Env-dir...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hayami M,Igarashi T

    更新日期:1997-04-01 00:00:00

  • LIF mRNA expression is transcriptionally regulated in murine bone marrow stromal cells.

    abstract::Recent evidence has established an important role for leukemia inhibitory factor (LIF) as hematopoietically active cytokine. The present study utilized two different murine bone marrow stromal cell lines, +/+-1.LDA11 and MBA-13, to define regulatory mechanisms of LIF messenger RNA (mRNA) induction. LIF mRNA was not de...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Derigs HG,Boswell HS

    更新日期:1993-04-01 00:00:00

  • The Eighth International Childhood Acute Lymphoblastic Leukemia Workshop ('Ponte di legno meeting') report: Vienna, Austria, April 27-28, 2005.

    abstract::The International Acute Lymphoblastic Leukemia Working Group, the so-called 'Ponte di Legno Workshop' has led to substantial progress in international collaboration in leukemia research. On April 27-28, 2005, the 8th Meeting was held in Vienna, Austria, to continue the discussions about special common treatment elemen...

    journal_title:Leukemia

    pub_type:

    doi:10.1038/sj.leu.2404016

    authors: Gadner H,Masera G,Schrappe M,Eden T,Benoit Y,Harrison C,Nachman J,Pui CH

    更新日期:2006-01-01 00:00:00

  • Effect of hyperthermia on both primary proliferation and self-renewal of human leukemic progenitor cells in vitro: its application to in vitro purging.

    abstract::Self-renewal, as defined by the capacity to yield new colonies following replating, is an important function of leukemic progenitors (L-CFU) to originate self-maintaining clones. In this work, we studied the effect of hyperthermia (41-44 degrees C) on the growth of human L-CFU derived primary colonies and of secondary...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Moriyama Y,Nikkuni K,Saito H,Aoki A,Kishi K,Takahashi M,Shibata A

    更新日期:1991-04-01 00:00:00

  • Cancer increases risk of in-hospital death from COVID-19 in persons

    abstract::The impact of cancer on outcome of persons with coronavirus disease 2019 (COVID-19) after infection with acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is controversial. We studied 1859 subjects with COVID-19 from seven centers in Wuhan, China, 65 of whom had cancer. We found having cancer was an independent ri...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0986-7

    authors: Li Q,Chen L,Li Q,He W,Yu J,Chen L,Cao Y,Chen W,Di Wu,Dong F,Cai L,Ran Q,Li L,Liu Q,Ren W,Gao F,Wang H,Chen Z,Gale RP,Hu Y

    更新日期:2020-09-01 00:00:00

  • The promotion of plasmacytoma tumor growth by mesenchymal stroma is antagonized by basic fibroblast growth factor induced activin A.

    abstract::The mesenchymal stroma has been shown to play a crucial role in the development of multiple myeloma, partly by secretion of interleukin (IL)-6, that serves as a growth factor for myeloma cells. However, it is still unclear which other stromal molecules are involved in the pathogenesis of this disease. We chose, as a m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402145

    authors: Shoham T,Sternberg D,Brosh N,Krupsky M,Barda-Saad M,Zipori D

    更新日期:2001-07-01 00:00:00

  • High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403057

    authors: Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

    更新日期:2003-09-01 00:00:00

  • Translocation t(8;13) in a patient with T cell lymphoma and features of a myeloproliferative syndrome.

    abstract::A 32-year-old white woman was admitted with a diagnosis of T lymphoblastic lymphoma and a bone marrow and peripheral blood cytology that was suggestive of a myeloproliferative syndrome (MPS). In addition, islets of myeloid precursors were found in the lymph node where the lymphoma had been diagnosed. Cytogenetic exami...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Behringer D,Schaefer HE,Kunzmann R,Mertelsmann R,Dölken G

    更新日期:1995-06-01 00:00:00

  • Characterisation of non-concordance in the T-cell receptor gamma chain genes at presentation and clinical relapse in acute lymphoblastic leukemia.

    abstract::We have analysed the structure of the T-cell receptor gamma chain (TCRG) genes in a panel of biopsies taken from 24 patients with acute lymphoblastic leukemia (ALL) (13 cALL, one pre-B ALL, two null ALL and eight T-ALL) at presentation and at clinical relapse. In the majority of cases (18/24) the structure of these ge...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Taylor JJ,Rowe D,Kylefjord H,Chessells J,Katz F,Proctor SJ,Middleton PG

    更新日期:1994-01-01 00:00:00

  • Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.

    abstract::The fusion transcript AML1/ETO corresponding to translocation t(8;21)(q22;q22) can be found in approximately 7-12% of childhood de novo AML. Despite the favorable prognosis, some of these patients relapse. Most of MRD studies so far were performed on adults treated not uniformly. Therefore, we analyzed the follow-up o...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2402959

    authors: Viehmann S,Teigler-Schlegel A,Bruch J,Langebrake C,Reinhardt D,Harbott J

    更新日期:2003-06-01 00:00:00

  • A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy.

    abstract::All-trans-retinoic acid (ATRA) is highly active in acute promyelocytic leukemia but not in other types of acute myeloid leukemia (AML). Previously, we showed that ATRA in combination with Lysine-specific demethylase 1 (LSD1) inhibition by tranylcypromine (TCP) can induce myeloid differentiation in AML blasts. This pha...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0892-z

    authors: Wass M,Göllner S,Besenbeck B,Schlenk RF,Mundmann P,Göthert JR,Noppeney R,Schliemann C,Mikesch JH,Lenz G,Dugas M,Wermke M,Röllig C,Bornhäuser M,Serve H,Platzbecker U,Foerster KI,Burhenne J,Haefeli WE,Müller LP,Bind

    更新日期:2020-06-19 00:00:00

  • BIOMED-I concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings. BIOMED-1 Concerted Action Investigation of Minimal Residual Disease in Acute Leukemia: International Standardization and Clinical Ev

    abstract::The flow cytometric detection of minimal residual disease (MRD) in precursor-B-acute lymphoblastic leukemias (precursor-B-ALL) mainly relies on the identification of minor leukemic cell populations that can be discriminated from their normal counterparts on the basis of phenotypic aberrancies observed at diagnosis. Th...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402150

    authors: Lucio P,Gaipa G,van Lochem EG,van Wering ER,Porwit-MacDonald A,Faria T,Bjorklund E,Biondi A,van den Beemd MW,Baars E,Vidriales B,Parreira A,van Dongen JJ,San Miguel JF,Orfao A,BIOMED-I.

    更新日期:2001-08-01 00:00:00

  • Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.

    abstract::Peripheral arterial occlusive disease (PAOD) occurs in patients with chronic phase chronic myeloid leukemia (CML-CP) treated with tyrosine kinase inhibitors (TKIs). The risk of developing PAOD on TKI therapy is unknown and causality has not been established. Patients with CML-CP from three randomized phase III studies...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.69

    authors: Giles FJ,Mauro MJ,Hong F,Ortmann CE,McNeill C,Woodman RC,Hochhaus A,le Coutre PD,Saglio G

    更新日期:2013-06-01 00:00:00

  • Cyclooxygenase-1, but not -2, is upregulated in NB4 leukemic cells and human primary promyelocytic blasts during differentiation.

    abstract::Cyclooxygenase (COX)-1 or -2 and specific prostaglandin (PG) synthases catalyze the formation of various PGs. We investigated the expression and activity of COX-1 and -2 during granulocyte-oriented maturation induced by all-trans-retinoic acid (ATRA) of NB4 cells, originated from a human acute promyelocytic leukemia (...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403407

    authors: Rocca B,Morosetti R,Habib A,Maggiano N,Zassadowski F,Ciabattoni G,Chomienne C,Papp B,Ranelletti FO

    更新日期:2004-08-01 00:00:00

  • Current recommendations for positive controls in RT-PCR assays.

    abstract::The choice of adequate controls for reverse transcriptase (RT-) PCR analysis has been the focus of a debate pursued in Leukemia over the past 3 years. Twenty-six authors from 15 different centers contributed to the Debate, and the points presented have been carefully evaluated. This survey reviews the issues discussed...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402133

    authors: Lion T

    更新日期:2001-07-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract::Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0416-x

    authors: Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期:2019-09-01 00:00:00

  • Biologic response modifiers in acute lymphoblastic leukemia.

    abstract::Despite the presence of tumor antigens, the paucity of clinically significant T-cell mediated immune responses against human tumors is striking. This may, in part, be because of the inability of cancer cells to function as efficient antigen-presenting cells. For full activation, T cells must receive two signals delive...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Gribben JG,Cardoso AA,Schultze JL,Nadler LM

    更新日期:1997-05-01 00:00:00